Method and kit for enhancing extraction and quantification of target molecules using microdialysis

• US 20040248181A1
• Filed: 06/01/2004
• Published: 12/09/2004
• Est. Priority Date: 06/03/2003
• Status: Abandoned Application

• Current Assignee: Albany Medical College (Albany Medical Center), Rensselaer Polytechnic Institute
• Original Assignee: Albany Medical College (Albany Medical Center)
• Inventors: Stenken, Julie A., Sellati, Timothy J.
• Application Number:
  US10/858,219
• Publication Number:
  US 20040248181A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61B 5/0059 using light, e.g. diagnosis by transillumination, diascopy, fluorescence A61B5/0093, A61B5/1455, A61B5/02416 and A61B5/0261 take precedence
• CPC Class Codes: A61B 5/14528 invasively
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/411 Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
• CPC Class Codes: A61B 5/686 Permanently implanted devices, e.g. pacemakers, other stimulators, biochips A61B5/6861 takes precedence
• CPC Class Codes: G01N 33/53 Immunoassay; Biospecific binding assay; Materials therefor
• CPC Class Codes: G01N 33/54366 Apparatus specially adapted for solid-phase testing

Abstract

The present invention is directed to a method for detection of a presence of one or more target molecules in a sample. This method involves providing a microdialysis unit having a membrane which defines within it a dialysate-containing region and contacting the microdialysis unit with a sample, potentially containing one or more target molecules, under conditions effective to permit molecules in the sample to permeate the membrane and enter the dialysate-containing region as a dialysate. A perfusate liquid comprising capture agents which are specific to the one or more target molecules and are immobilized to solid structures is provided and contacted with the dialysate (desirably within the dialysate-containing region) under conditions effective to permit target molecules present in the dialysate, if any, to specifically bind to the capture agents immobilized to the solid structures. As a result, a dialysate liquid potentially comprising dialysate complexes of target molecules bound to capture agents, which are immobilized to solid structures, is formed. The dialysate liquid is analyzed for dialysate complexes. As a result, the presence of the one or more target molecules in the sample is detected. A kit for carrying out this method is also disclosed.

Claims

1. A method for detection of a presence of one or more target molecules in a sample, said method comprising:

providing a microdialysis unit having a membrane which defines within it a dialysate-containing region;

contacting the microdialysis unit with a sample, potentially containing one or more target molecules, under conditions effective to permit molecules in the sample to permeate the membrane and enter the dialysate-containing region as a dialysate;

providing a perfusate liquid comprising capture agents which are specific to the one or more target molecules and are immobilized to solid structures;

contacting the perfusate liquid with the dialysate under conditions effective to permit target molecules present in the dialysate, if any, to specifically bind to the capture agents immobilized to the solid structures, thereby forming a dialysate liquid potentially comprising dialysate complexes of target molecules bound to capture agents which are immobilized to solid structures; and

analyzing the dialysate liquid for dialysate complexes, thereby detecting the presence of the one or more target molecules in the sample.

2. The method according to claim 1, wherein the one or more target molecules are biomolecules.

3. The method according to claim 2, wherein the one or more target molecules are antigens and the capture agents comprise antibodies or binding portions thereof specific to each of the antigens.

4. The method according to claim 2, wherein the one or more target molecules are antibodies and the capture agents comprise antigens specific to each of the antibodies.

5. The method according to claim 2, wherein the one or more target molecules are nucleic acid molecules and the capture agents comprise nucleic acid molecules complementary to the target molecules.

6. The method according to claim 2, wherein the biomolecule is selected from the group consisting of cytokines, chemokines, eicosanoids, prostaglandins, leukotrienes, and peptides.

7. The method according to claim 1, wherein the target molecules are drugs, drug metabolites, or pharmacophores.

8. The method according to claim 1, wherein said contacting the microdialysis unit with a sample is carried out ex vivo.

9. The method according to claim 1, wherein said contacting the microdialysis unit with a sample is carried out in vivo.

10. The method according to claim 1, wherein the microdialysis unit has a linear form.

11. The method according to claim 1, wherein the microdialysis unit has a cannula form.

12. The method according to claim 1, wherein the solid structures are selected from the group consisting of microspheres and nanocrystals.

13. The method according to claim 1, wherein said analyzing is carried out by detecting a label which is coupled directly or indirectly to the capture agents and the solid structures.

14. The method according to claim 13, wherein the labels for different target molecules are the same type of label but differ from one another in intensity.

15. The method according to claim 14, wherein the labels for different target molecules are different types of labels.

16. The method according to claim 15, wherein the labels are selected from the group consisting of nanocrystals, chromophores, fluorescent moieties, dyes, phosphorescent groups, and chemiluminescent moieties.

17. The method according to claim 16, wherein the solid structures are labeled.

18. The method according to claim 17, wherein the labels for the solid structures and the labels coupled directly or indirectly to the capture agents and the solid structures are the same type of label but the labels coupled directly or indirectly to the capture agents and the solid structures differ from one another, for the different target molecules, in intensity to allow for quantitation of the target molecules present in the sample, while the labels of the solid structure serve to discriminate between different target molecules.

19. The method according to claim 18, wherein the labels are selected from the group consisting of nanocrystals, chromophores, fluorescent moieties, dyes, phosphorescent groups, and chemiluminescent moieties.

20. The method according to claim 17, wherein the labels for the solid structures are the same type of label and the labels coupled directly or indirectly to the capture agents and the solid structures are different types of labels to allow for quantitation of the target molecules present in the sample, while the labels of the solid structure serve to discriminate between different target molecules.

21. The method according to claim 20, wherein the labels are selected from the group consisting of nanocrystals, chromophores, fluorescent moieties, dyes, phosphorescent groups, and chemiluminescent moieties.

22. The method according to claim 1, wherein said analyzing is carried out with a sandwich assay format, said method further comprising:

contacting the dialysate liquid with a detection molecule specific for a particular target molecule and coupled to a label under conditions effective to form labeled dialysate complexes.

23. The method according to claim 1, wherein said analyzing is carried out with a competitive assay format, said method further comprising:

contacting the dialysate liquid with a labeled target molecule under conditions effective to cause the capture agents immobilized to the solid structures to be bound to the labeled target molecule, thereby permitting indirect detection of dialysate complexes.

24. The method according to claim 1 further comprising:

quantifying the one or more target molecules detected as being present in the sample.

25. The method according to claim 24, wherein said analyzing and said quantitating are carried out by flow cytometry.

26. The method according to claim 1, wherein said analyzing is carried out by flow cytometry.

27. The method according to claim 1, wherein said method is used to detect or monitor a disease state.

28. The method according to claim 27, wherein the disease state is caused by a pathogen selected from the group consisting of bacteria, viruses, fungi, and parasites.

29. The method according to claim 27, wherein the disease state has an origin which is either non-infectious, inflammatory, hematological, neurological, social stress, eating, autoimmune, allergic, immune deficiency, or cancer.

30. The method according to claim 1, wherein said method is used to monitor progress of treating a subject having a disease state with a pharmaceutical agent.

31. The method according to claim 30, wherein the disease state has an origin which is either infectious, non-infectious, inflammatory, hematological, neurological, social stress, eating, autoimmune, allergic, immune deficiency, or cancer.

32. The method according to claim 1, wherein said method is used to screen a candidate compound for therapeutic efficacy in treating a subject for a disease state.

33. The method according to claim 32, wherein said method is used to monitor a candidate compound'"'"'s ability to alter levels of biological response modifiers that are either elevated or suppressed by the disease state.

34. The method according to claim 32, wherein the disease state has an origin which is either infectious, non-infectious, inflammatory, hematological, neurological, social stress, eating, autoimmune, allergic, immune deficiency, or cancer.

35. The method according to claim 1, wherein the presence of a plurality of target molecules in a sample are detected.

36. The method according to claim 1, wherein said contacting the perfusate liquid with the dialysate is carried out within the dialysate containing region.

37. A kit for detection of a presence of one or more target molecules in a sample, said kit comprising:

a microdialysis unit having a membrane;

capture agents which are specific to the one or more target molecules and are immobilized to solid structures; and

labeling agents for labeling either;

(1) any of the target molecules with a label specific for a particular target molecule or (2) the capture agents which are specific to the one or more target molecules and immobilized to the solid structures.

38. The kit according to claim 37, wherein the capture agents are specific for one or more target molecules that are biomolecules.

39. The kit according to claim 37, wherein the one or more target molecules are antigens and the capture agents comprise antibodies or binding portions thereof specific to the antigens.

40. The kit according to claim 38, wherein the one or more target molecules are nucleic acid molecules and the capture agents comprise nucleic acid molecules complementary to the target molecules.

41. The kit according to claim 38, wherein the biomolecule is selected from the group consisting of cytokines, chemokines, eicosanoids, prostaglandins, leukotrienes, and peptides.

42. The kit according to claim 37, wherein the target molecules are selected from the group consisting of drug metabolites, pharmacophores, and drugs.

43. The kit according to claim 37, wherein the microdialysis unit has a linear form.

44. The kit according to claim 37, wherein the microdialysis unit has a cannula form.

45. The kit according to claim 37, wherein the solid structures are selected from the group consisting of microspheres and nanocrystals.

46. The kit according to claim 37, wherein the labels for different target molecules are the same type of label but differ from one another in intensity.

47. The kit according to claim 37, wherein the labels for different target molecules are different types of labels.

48. The kit according to claim 37, wherein the labels are selected from the group consisting of nanocrystals, chromophores, fluorescent moieties, dyes, phosphorescent groups, and chemiluminescent moieties.

49. The kit according to claim 37, wherein the solid structures are labeled.

50. The kit according to claim 49, wherein the labels for the solid structures and the labels of the labeling agents are the same type of label but the labels of the labeling agents differ from one another in intensity so that the labels in the labeling agents allow for quantitation of the target molecules present in the sample, while the labels of the solid structure serve to discriminate between different target molecules.

51. The kit according to claim 50, wherein the labels are selected from the group consisting of nanocrystals, chromophores, fluorescent moieties, dyes, phosphorescent groups, and chemiluminescent moieties.

52. The kit according to claim 49, wherein the labels for the solid structures are the same type of label and the labels of the labeling agents are different types of labels so that the labels of the labeling agents allow for quantitation of the target molecules present in the sample, while the labels of the solid structure serve to discriminate between different target molecules.

53. The kit according to claim 52, wherein the labels are selected from the group consisting of nanocrystals, chromophores, fluorescent moieties, dyes, phosphorescent groups, and chemiluminescent moieties.

54. The kit according to claim 37, wherein the kit is in a sandwich assay format with the labeling agent comprising a detection molecule specific for a particular target molecule and coupled to a label, whereby the labeling agent binds to target molecules bound to the capture agents immobilized to the solid structures.

55. The kit according to claim 37, wherein the kit is in a competitive assay format with the labeling agent comprising a labeled target molecule, whereby labeled target molecule binds to the capture agents immobilized to the solid structures, thereby permitting indirect detection of dialysis complexes formed from target molecules bound to the capture agents.